These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31982262)

  • 21. Combination of Modified NS1 and NS3 as a Novel Vaccine Strategy against Dengue Virus Infection.
    Kao YS; Yu CY; Huang HJ; Tien SM; Wang WY; Yang M; Anderson R; Yeh TM; Lin YS; Wan SW
    J Immunol; 2019 Oct; 203(7):1909-1917. PubMed ID: 31451673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
    Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
    Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.
    García-Machorro J; López-González M; Barrios-Rojas O; Fernández-Pomares C; Sandoval-Montes C; Santos-Argumedo L; Villegas-Sepúlveda N; Gutiérrez-Castañeda B; Cedillo-Barrón L
    Hum Vaccin Immunother; 2013 Nov; 9(11):2326-35. PubMed ID: 23880886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice.
    Feng K; Zheng X; Wang R; Gao N; Fan D; Sheng Z; Zhou H; Chen H; An J
    Front Cell Infect Microbiol; 2020; 10():87. PubMed ID: 32257963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes.
    Gao G; Wang Q; Dai Z; Calcedo R; Sun X; Li G; Wilson JM
    Hum Gene Ther; 2008 Sep; 19(9):927-36. PubMed ID: 18788905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature.
    Pintado Silva J; Fenutria R; Bernal-Rubio D; Sanchez-Martin I; Hunziker A; Chebishev E; Veloz J; Kelly G; Kim-Schulze S; Whitehead S; Durbin A; Ramos I; Fernandez-Sesma A
    Exp Biol Med (Maywood); 2022 Dec; 247(24):2201-2212. PubMed ID: 36734144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    J Nanobiotechnology; 2012 Jul; 10():30. PubMed ID: 22794664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice.
    Gao N; Li J; Sheng Z; Chen H; Fan D; Wang P; An J
    Appl Microbiol Biotechnol; 2019 Jun; 103(12):4977-4986. PubMed ID: 31037380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
    Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
    Front Immunol; 2019; 10():59. PubMed ID: 30761131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
    Apt D; Raviprakash K; Brinkman A; Semyonov A; Yang S; Skinner C; Diehl L; Lyons R; Porter K; Punnonen J
    Vaccine; 2006 Jan; 24(3):335-44. PubMed ID: 16125280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production and immunogenicity of Fubc subunit protein redesigned from DENV envelope protein.
    Rathore AS; Sarker A; Gupta RD
    Appl Microbiol Biotechnol; 2020 May; 104(10):4333-4344. PubMed ID: 32232529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins.
    Nadugala MN; Jeewandara C; Jadi RS; Malavige GN; de Silva AM; Premaratne PH; Goonasekara CL
    BMC Immunol; 2021 Nov; 22(1):71. PubMed ID: 34732126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
    Swanstrom JA; Nivarthi UK; Patel B; Delacruz MJ; Yount B; Widman DG; Durbin AP; Whitehead SS; De Silva AM; Baric RS
    J Infect Dis; 2019 Jun; 220(2):219-227. PubMed ID: 30895307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice.
    Hou J; Shrivastava S; Fraser CC; Loo HL; Wong LH; Ho V; Fink K; Ooi EE; Chen J
    Front Immunol; 2019; 10():1429. PubMed ID: 31281322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.
    Zhao H; Jiang T; Zhou XZ; Deng YQ; Li XF; Chen SP; Zhu SY; Zhou X; Qin ED; Qin CF
    PLoS One; 2014; 9(1):e86573. PubMed ID: 24466156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.